Further to the announcement made by the Company on 2 March 2015, Mwana wishes to provide an update in respect of the notice to convene a general meeting of the Company's shareholders (the "Requisition") pursuant to section 303 of the Companies Act 2006 (the "Act") by Mr Ian Dearing and other shareholders (the "Requisitioners"), as further described in the previous announcement. Mwana has concluded its investigation into the validity of the Requisition of a general meeting and concluded that following the withdrawal from the Requisition of one of the original parties to it, the Requisitioners do not have sufficient support at the current time to require the directors to convene a general meeting under the Act. Correspondence has been received from solicitors acting for Mr Dearing disputing the Company's position, and threatening to attempt to try and convene a meeting of shareholders directly under section 305 of the Act. This position is rejected by the Company, which has reserved all its rights in the event of an attempt by Mr Dearing to convene a general meeting on the basis of the current level of support for the Requisition. Shareholders are advised to take no action at this time. Further announcements will be made as required in due course. Separately, Mwana also announces today that it will be publishing its Quarterly Operational Update for the three months ending 31 March 2015 on 16 April 2015. For further information please visit www.mwanaafrica.com
global provider of performance, knowledge, and learning management systems, is pleased to announce that it will be a presenting company at the UK Investor Show 2015. NetDimensions Chief Executive Officer, Jay Shaw and Chief Financial Officer, Matthew Chaloner will be presenting at 13:45 in Whittle Seminar Theatre A. In addition to the presentation the NetDimensions management team will also be available throughout the day at the Company's exhibition stand, F36. The show will be held on Saturday 18 April 2015 at Queen Elizabeth II Centre, Broad Sanctuary, Westminster, London. For more details about the Show please visit the following website https://www.ukinvestorshow.com/
NETD will be reporting its preliminary results for the year ended 31 December 2014 on Monday 13 April 2015. The management team will be hosting a briefing for analysts on the day at 9:30am at The London Capital Club, 15 Abchurch Lane, London, EC4N 7BW. If you wish to attend, or require further information, please contact Sam Allen or Nick Rome at Walbrook PR on 020 7933 8790 or email netdimensions@walbrookpr.com to register.
That still undervalues POL on the sum parts of its businesses.
Michael Tang, Executive Chairman of Polo, said: "We were very fortunate to be heading into this period with a healthy balance sheet, significantly strengthened by cash reserves from our oil and gas investments, which has enabled us to expand our interests in the copper and phosphate sectors. "In the near term, we will continue looking to grow our portfolio following our strategy to support near-term producers with proven resources, professional management teams and inherent upside potential. However, we are mindful that operating in developing countries could expose us to unforeseen events beyond our control, such as political instability and the recent Ebola crisis. "However, our emphasis on gathering research and technical assessments in shortlisting sound investment opportunities enables the Company to hedge its risk and offer investors a more balanced exposure to the metals, mining and energy sectors."
Financial Highlights · Total Net Assets of US$114.3 million as of 25 March 2015 (31 December 2014: US$117.0 million). · Net Asset Value per share as at 25 March 2015 was approximately 27.7 pence per share (31 December 2014: 27.2 pence per share). http://www.londonstockexchange.com/exchange/news/market-news/market-news-detail/12296400.html
Announce that is has entered into a partnership agreement with O2, part of Telefonica (UK) Limited, enabling the Company to provide O2's mobile, digital and accredited public sector solution services to Pinnacle's client base. As part of the agreement, Pinnacle will be joining the exclusive category of O2's direct partner network and receive commercially advantageous terms. The deal builds on the existing relationship between Pinnacle and O2 whereby, as an accredited supplier of mobile telephony solutions for O2, Pinnacle offers a wide range of flexible tariffs and contracts, with a variety of package options available. This new agreement means that Pinnacle will partner with O2 in supporting its digital ambitions and also be able to access its digital supplier relationships- such as those with Microsoft and McAfee. This agreement also enables Pinnacle to provide public sector organisations with a complete turnkey solution through the Public Services Network (PSN) framework. O2, as the first mobile network provider to become CAS(T) certified will, through its partnership with Pinnacle, enable the Company to offer enhanced IT security to the public sector. Taken together, Pinnacle's service offering represents a strong proposition to the public sector and the opportunity for the Company to meet the increasing market demand for heightened security capabilities to deal with electronic security threats. Pinnacle CEO, Nicholas Scallan, said: "Our exciting partnership with O2 is another demonstration of our on-going commitment to offering clients technology, digital products and services that will significantly enhance their business. We further believe that being able to offer both existing and new public sector clients PSN-assured services is highly appropriate in the current climate, where cyber security is increasingly important to both the public and private sectors."
Hi pablo2: "In summary, the Group continues to invest to create an organisation with the potential to deliver revenues and profits on a significantly higher scale than has been achieved in prior years. The Board is very appreciative of the Group's shareholders, whose investment and continued support has enabled the Group to create a stable working capital base to fund this exciting phase in its development, and look forward to the future with confidence."
http://www.londonstockexchange.com/exchange/news/market-news/market-news-detail/12289939.html
provides a draft interim analysis of Atu027-I-02 Phase IIa study in pancreatic cancer. The primary objective of this trial was to assess safety and pharmacokinetics, and the secondary objective was to evaluate efficacy, including Progression Free Survival (PFS). This study was open label in 23 patients with incurable pancreatic cancer and included two treatment arms with Atu027 in combination with the standard of care, gemcitabine. Treatment arm 1 delivered one dose per week for three weeks, followed by one week of no treatment, giving a total of 6 administrations in 8 weeks. Treatment arm 2 delivered 2 doses per week during 4 weeks, followed by 4 weeks of no treatment, a total of 8 administrations in 8 weeks. Arm 2 therefore received 33% more Atu027 during the same treatment period. The presented results are preliminary but have been generated by an independent clinical research organisation. Tolerability and platform validation There was no difference in safety events leading to discontinuation between the two arms, with one subject withdrawing because of an adverse event in each arm. Atu027 was generally well tolerated. In addition, the study results are an important further validation of Silence's two-component drug -a short interfering RNA (siRNA) and a delivery system. Over 400 patients have now been treated with the Company's proprietary modified siRNA (AtuRNAi®), with excellent tolerability. In regards to delivery, this data gives further evidence of the favourable safety profile of Silence's delivery platforms, which are the core components of the Company's 'multiple shots at goal' strategy. Progression free survival A preliminary analysis of this open label study indicates that the subjects who were exposed to a 33% higher total dose of Atu027 had a longer duration of PFS (median of 5.33 months) than patients on the lower exposure regimen (median of 1.81 months). This suggests that in this study, a dose-dependent effect was seen for Atu027. Ali Mortazavi, CEO of Silence Therapeutics, said: "Even allowing for the small number of patients in the trial, these results show a clear signal which requires further investigation. Atu027 has the potential to become a new therapeutic modality in oncology. This is an excellent outcome both in terms of Atu027 and validation of our RNA therapeutics platform. In light of this data, we are reviewing the protocol for the planned Phase Ib head and neck cancer study. "In addition to the clinical development of Atu027, Silence Therapeutics has a wide range of pre-clinical projects based on its ability to modulate gene expression both on and off. We look forward to the future with great confidence."
http://www.londonstockexchange.com/exchange/news/market-news/market-news-detail/12284883.html
year ended 31 December 2014. Key points: · Operational o Order book maintained to close at £20 million (2013: £20 million) o Secured five year framework agreement with Siemens Mobility Division for the supply of Petards train related products and services under which over £3 million of orders received to date o Other significant orders secured during the year included: § Over £5.5 million for electronic countermeasure related projects from the MOD § Re-awarded framework contract by MOD to supply to it private mobile radio equipment, ancillaries and engineering support § Further orders from other leading global train builders including Bombardier Transportation and Hitachi Europe · Financial o Petards returns to profitability o Results for 2014 § Revenues more than doubled to £13.5 million (2013: £6.3 million) § Gross margin 30% (2013: 40%) reflecting higher defence-related equipment revenues § EBITDA £1.0 million profit (2013: £0.7 million loss) § Operating profit £0.8 million (2013: £1.3 million loss) § Profit after tax £0.6 million (2013: £2.3 million loss) o Finance § Generated £0.8 million of operating cash inflows § Cash at 31 December 2014 £1.4 million (31 Dec 2013: £1.4 million) and no bank debt § Convertible loan notes of £1.5 million maturing in September 2018 providing long term finance (31 Dec 2013: £1.5 million) § Basic EPS of 1.8p earnings per share (2013: 15.9p loss per share) § Diluted EPS of 1.4p earnings per share (2013: 15.9p loss per share) · Outlook o Over 50% of opening order book scheduled for delivery in 2015 o Performance in 2015 to date in line with management's expectations Raschid Abdullah, Chairman of Petards, commented: "I am pleased to say for the year to date the Group has traded in line with expectations and that it remains well placed to add to the achievements of 2014. The visibility provided by the Group's current forward order book and its pipeline of order prospects provides the Board with confidence that further progress will be made in 2015."
The announcement of a placing made earlier today by Lansdowne Oil & Gas plc ("Lansdowne") and confirms that SEA did not participate in the placing. As a result its shareholding in Lansdowne remains unchanged at 30,194,193 shares although its percentage holding will be diluted to 18.72% once the placing shares are issued on 12 March 2015.
Hi Been following this developing story for some time. http://www.lse.co.uk/general-chat-discussion.asp?page=1&TopCode=SC2SL2IH
Today 10:29GedWECV on the lookout...0.01No Opinion ... for media and technology. Does MTV fit the bill of an attractive growth prospect vehicle. John Swingewood, Chairman of the Company ("ECV"), commented: "The return to trading of the Shares completes the first phase of achieving value for shareholders after a difficult period. The Board and its advisors are actively seeking to identify suitable acquisition targets: companies in the media and technology sectors, with solid business models and attractive growth prospects."
News relates to FTE
http://www.londonstockexchange.com/exchange/news/market-news/market-news-detail/12261995.html